Drug Profile
PMZ 2123
Alternative Names: BQ-123; CGS 26343; PMZ-2123Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Midwestern University
- Developer Banyu; Pharmazz; University of Glasgow; Western Infirmary
- Class Cyclic peptides
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic ketoacidosis; Pain
- Discontinued Arrhythmias; Cerebral ischaemia; Diabetic complications; Heart failure; Hypertension; Hypertension in pregnancy; Myocardial ischaemia; Peripheral vascular disorders; Stress ulcer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Diabetic-ketoacidosis in USA (IV)
- 14 Feb 2022 PMZ 2123 is still in phase-I trials for Diabetic-ketoacidosis in USA (IV) (Pharmazz pipeline, February 2022)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Diabetic-ketoacidosis in USA (IV)